SCIENTIFIC EVIDENCE

Dissecting the Distinct Tumor Microenvironments of HRD and HRP Ovarian Cancer: Implications for Targeted Therapies to Overcome PARPi Resistance in HRD Tumors and Refractoriness in HRP Tumors.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Qiu J, Ren T, Liu Q, Jiang Q, Wu T, Cheng LC, Yan W, Qu X, Han X, Hua K.

Publication Overview

Key findings, Countstar context, and access to the original paper.
2024
Cancer Research
Immunology
Single-Cell Analysis
No items found.
Key Finding
Single-cell profiling showed that homologous-recombination-deficient and -proficient high-grade serous tubo-ovarian cancers contain distinct epithelial, fibroblast, macrophage, and T-cell states. These differences identified separate therapeutic opportunities for PARP-inhibitor-resistant HRD tumors and poorly responsive HRP tumors.
Countstar Connection
Countstar (model not specified) quantified cell viability in the study's cell samples before single-cell analysis in the 2024 Advanced science study.
View paper ↗
Stay Connected toCountstar Science
Get new publications, application notes, cell analysis insights, and Countstar updates delivered to your inbox.
Meet us online
Products
About Us
Contact
© 2026 Countstar. All rights reserved.